Destiny Pharma Phase 2b trial of XF-73 completes recruitment
Link to Full Article Phase 2b clinical trial of XF-73 completes patient recruitment Results expected in Q1 2021 Brighton, United Kingdom – 5th January 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, today announces that its XF-73 […]